BlackRock Health Sciences Opportunities Portfolio
SHSCX
NASDAQ- -
USD
- -
- -
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Financial Services
- Industry
- Asset Management
- Address
- 100 Bellevue Parkway Wilmington DE United States of America 19809
- IPO Date
- Oct 16, 2000
- CIK
- 0000844779
- Website
- blackrock.com
- Similar Companies
- Business
- BlackRock Health Sciences Opportunities Portfolio (SHSCX) is an open-end mutual fund that seeks long-term capital growth primarily through investment in equity securities of companies operating in health sciences and related industries; it normally invests at least 80% of its total assets in such securities, including common stocks of pharmaceutical, biotechnology, life sciences, health care services, medical technology, and health care facilities firms; the fund may also invest in companies located in non-U.S. countries and employs a fundamental research-driven approach enhanced by scientific expertise to access innovative healthcare equities while aiming for diversified returns with lower volatility. The Investor C share class carries a gross expense ratio of 1.85%, features holdings such as Johnson & Johnson (8.20%), Eli Lilly and Company (7.78%), Abbott Laboratories (5.97%), AbbVie Inc. (4.71%), and UnitedHealth Group Inc. (4.21%), and targets individual and institutional investors seeking sector-specific exposure in the healthcare industry. Managed by BlackRock Advisors, LLC, a subsidiary of BlackRock, Inc., the fund operates globally with primary focus on U.S. markets and is part of BlackRock's broader suite of equity mutual funds offered through various share classes including Institutional (SHSSX), Investor A (SHSAX), and Service (SHISX). Launched in 2000 as part of BlackRock's health sciences offerings following the firm's founding in 1988, the fund is headquartered at 50 Hudson Yards, New York, New York, aligning with BlackRock's global investment management operations across 30 countries. In recent developments, the fund has maintained steady performance amid healthcare sector volatility, delivering a 1-year total return of -6.23% and 10-year annualized return of 8.56% as of late 2025, while BlackRock announced its agreement to acquire HPS Investment Partners in December 2024, expected to close in mid-2025 and expand private markets capabilities that could indirectly benefit fund strategies through enhanced research resources; no fund-specific acquisitions, new product launches, or reorganizations were reported in the last 1-2 years.